Gain exclusive access to more than 200,000 scientifically curated, quality‑tested legacy biospecimens, including PBMCs, plasma, leukopaks, BMMCs, and DTCs, enabling fast, cost‑effective insights. The program supports biomarker discovery, assay validation, target identification, longitudinal studies, and large‑scale AI model development. The collection expands continuously as new biospecimens age into eligibility, ensuring a steady pipeline of high‑value samples for advanced research.
Discovery’s consented inventory quality is driven by single chain-of-custody, short intervals from collection to processing, and proper sample handling and storage for the full life of the material. Cells from diseased patients vary in count and viability; make informed sample selection with Discovery’s post-thaw data included on every inventory report.
Figure 1: Viable Cells Counts and Cell Viability measured at initial QC (x-axis) and after storage (y-axis) show strong concordance.
Properly stored, cryopreserved samples can remain stable for decades; but progress doesn’t happen in freezers. The Legacy Program keeps our inventory dynamic, ensuring patient-contributed samples continue to drive discovery.
